US Patent

US10052313 — Compositions and methods for the treatment of presbyopia

Method of Use · Assigned to Presbyopia Therapies Inc · Expires 2034-03-24 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a polyol. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.

USPTO Abstract

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a polyol. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3741 —

Patent Metadata

Patent number
US10052313
Jurisdiction
US
Classification
Method of Use
Expires
2034-03-24
Drug substance claim
No
Drug product claim
Yes
Assignee
Presbyopia Therapies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.